|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Glenmark Pharmaceuticals Signs Asthma Drug Deal With Japanese Firm; $53 Million
10/19/2005 5:10:53 PM
BOMBAY, April 26 (Reuters) - India's Glenmark Pharmaceuticals Ltd. (GLEN.BO: Quote, Profile, Research) said on Tuesday it had licensed an asthma treatment molecule to Teijin Pharma Ltd. for development and marketing in Japan, in a deal worth up to $53 million.
This follows a tie-up with U.S. rival Forest Labs Inc. (FRX.N: Quote, Profile, Research) for development and marketing of the drug, which aims to treat chronic obstructive pulmonary disorder (COPD), in North America. The deal with Forest, worth up to $190 million, is the largest licensing agreement struck by any Indian drug maker.
|
|
|
|
|
|
|
|
|
|
|